PuSH - Publikationsserver des Helmholtz Zentrums München

Dumont, M.* ; Weber-Lassalle, N.* ; Joly-Beauparlant, C.* ; Ernst, C.* ; Droit, A.* ; Feng, B.* ; Dubois, S.* ; Collin-Deschesnes, A.* ; Soucy, P.* ; Vallee, M.* ; Fournier, F.* ; Lemacon, A.* ; Adank, M.A.* ; Allen, J.* ; Altmueller, J.* ; Arnold, N.* ; Ausems, M.G.E.M.* ; Berutti, R.* ; Bolla, M.K.* ; Bull, S.* ; Carvalho, S.* ; Cornelissen, S.* ; Dufault, M.R.* ; Dunning, A.M.* ; Engel, C.* ; Gehrig, A.* ; Geurts-Giele, W.R.R.* ; Gieger, C. ; Green, J.* ; Hackmann, K.* ; Helmy, M.* ; Hentschel, J.* ; Hogervorst, F.B.L.* ; Hollestelle, A.* ; Hooning, M.J.* ; Horvath, J.* ; Ikram, M.A.A.* ; Kaulfuss, S.* ; Keeman, R.* ; Kuang, D.* ; Luccarini, C.* ; Maier, W.* ; Martens, J.W.M.* ; Niederacher, D.* ; Nürnberg, P.* ; Ott, C.* ; Peters, A. ; Pharoah, P.D.P.* ; Ramirez, A.* ; Ramser, J.* ; Riedel-Heller, S.* ; Schmidt, G.* ; Shah, M.* ; Scherer, M.* ; Stäbler, A.* ; Strom, T.M.* ; Sutter, C.* ; Thiele, H.* ; van Asperen, C.J.* ; van der Kolk, L.* ; van der Luijt, R.B.* ; Volk, A.E.* ; Wagner, M.* ; Waisfisz, Q.* ; Wang, Q.* ; Wang-Gohrke, S.* ; Weber, B.H.F.* ; Devilee, P.* ; Tavtigian, S.* ; Bader, G.D.* ; Meindl, A.* ; Goldgar, D.E.* ; Andrulis, I.L.* ; Schmutzler, R.K.* ; Easton, D.F.* ; Schmidt, M.K.* ; Hahnen, E.* ; Simard, J.*

Uncovering the contribution of moderate-penetrance susceptibility genes to breast cancer by whole-exome sequencing and targeted enrichment sequencing of candidate genes in women of European ancestry.

Cancers 14:3363 (2022)
Postprint Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Rare variants in at least 10 genes, including BRCA1, BRCA2, PALB2, ATM, and CHEK2, are associated with increased risk of breast cancer; however, these variants, in combination with common variants identified through genome-wide association studies, explain only a fraction of the familial aggregation of the disease. To identify further susceptibility genes, we performed a two-stage whole-exome sequencing study. In the discovery stage, samples from 1528 breast cancer cases enriched for breast cancer susceptibility and 3733 geographically matched unaffected controls were sequenced. Using five different filtering and gene prioritization strategies, 198 genes were selected for further validation. These genes, and a panel of 32 known or suspected breast cancer susceptibility genes, were assessed in a validation set of 6211 cases and 6019 controls for their association with risk of breast cancer overall, and by estrogen receptor (ER) disease subtypes, using gene burden tests applied to loss-of-function and rare missense variants. Twenty genes showed nominal evidence of association (p-value < 0.05) with either overall or subtype-specific breast cancer. Our study had the statistical power to detect susceptibility genes with effect sizes similar to ATM, CHEK2, and PALB2, however, it was underpowered to identify genes in which susceptibility variants are rarer or confer smaller effect sizes. Larger sample sizes would be required in order to identify such genes.
Impact Factor
Scopus SNIP
Altmetric
6.575
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Breast Cancer ; Genetic Susceptibility ; Whole-exome Sequencing ; Moderate-penetrance Genes
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2072-6694
Zeitschrift Cancers
Quellenangaben Band: 14, Heft: 14, Seiten: , Artikelnummer: 3363 Supplement: ,
Verlag MDPI
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
POF Topic(s) 30202 - Environmental Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504091-004
G-504000-010
Förderungen U.S. National Institutes of Health, National Center for Research Resources

Ministère de l'Économie, de la Science et de l'Innovation du Québec
the Government of Canada through Genome Canada and the Canadian Institutes of Health Re-search (GPH-129344), the Ministère de l'Économie, de la Science et de l'Innovation du Québec through Genome Quebec, and the Quebec Breast Cancer Foundation
Scopus ID 85136435285
PubMed ID 35884425
Erfassungsdatum 2022-09-01